

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,870,042 B1
DATED : March 22, 2005
INVENTOR(S) : Schlievert et al.

Page 1 of 2

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 1,

Line 10, insert the following paragraph:

-- Government Support

This invention was made with government support under Grant No. HL36611 from the U.S. National Institutes of Health. The government has certain rights in the invention. --.

Column 2,

Line 2, "TNT- α " should read -- TNF- α --.

Line 17, after "this pathology." insert the following sentence -- Certain single amino acid substitutions in central regions of the SPE-A molecule have been shown to affect the mitogenic activity of and binding to a HLA class II molecules by SPE-A (Hartwig et. al. International Immunology 5:5, 869-875 (1993)). --.

Line 32, "to human umbilical" should read -- to the human umbilical --.

Column 9,

Line 47, "useful in vaccine is" should read -- useful in vaccine --.

Column 12,

Line 33, "wild is type SPEA." should read -- wild type SPEA. --.

Column 13,

Line 47, "viva using fluorescence" should read -- vivo using fluorescence --.

Column 14,

Line 7, "amino aced sequence" should read -- amino acid sequence --.

Line 50, "wild type is SPE-A toxin" should read -- wild type SPE-A toxin --.

Line 67, "Compostions or" should read -- Compositions or --.

Column 16,

Line 67, "and 31 flanking" should read -- and 3' flanking --.

Column 18,

Line 39, "in Example S." should read -- in Example 5. --.

Line 51, "with chances in amino acid" should read -- with changes in amino acid --.

Column 22,

Line 49, "pBR328 (carrying Amp and" should read -- pBR328 (carrying Amp and Tet --.

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,870,042 B1
DATED : March 22, 2005
INVENTOR(S) : Schlievert et al.

Page 2 of 2

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Columns 25-26,

Line 48,

"5' -CCC CCC GTC GAC GAT AAA ATA GTT GCT AAG CTA CAA GCT-3' (SEQ ID NO:2)

Sal I"

should be in column 26 and not in column 25.

Column 31,

Line 20, "The double is mutant genes" should read -- The double mutant genes --.

Column 34,

Lines 5-6, "average titer with the titers" should read -- average titer with the other two mutants being comparable. However, the range of titers --.

Column 45,

Line 11, "fiber comprising a" should read -- further comprising a --.

Column 46,


Line 16, "ard encoding a polypeptide" should read -- and encoding a polypeptide --.

Line 17, "wild-type SPEA toxin; or" should read -- wild-type SPE-A toxin; or --.

Line 31, "comprising apolynucleotide" should read -- comprising a polynucleotide --.

Signed and Sealed this

Sixth Day of September, 2005

A handwritten signature in black ink, appearing to read "Jon W. Dudas". The signature is stylized with a large, looped initial "J" and a distinct "D" at the end.

JON W. DUDAS
Director of the United States Patent and Trademark Office